ASLAN Pharma up on antibody manufacturing pact with Thermo Fisher

Aslan Pharmaceuticals

03/01/2023 16:44

** U.S.-listed shares of Singapore-based biopharma co ASLAN
Pharmaceuticals Limited  ASLN.O  up ~12% at 40 cents 
    ** Co enters into a partnership with medical equipment maker
Thermo Fisher Scientific Inc  TMO.N  
    ** The pact is to manufacture a high concentration
formulation of ASLN's antibody eblasakimab for late-stage
studies in treating moderate-to-severe atopic dermatitis (AD) 
    ** AD, also known as eczema, is a non-contagious
inflammatory skin condition 
    ** TMO plans to commence manufacturing of the new
formulation in January 2023
    ** ASLN is currently evaluating the efficacy and safety of
eblasakimab in adult patients with moderate-to-severe AD, with
top-line data expected in Q2 of 2023 
    ** ASLN is also testing eblasakimab in a separate study with
AD patients who have previously been treated with antibody
dupilumab; study data expected in the Q1 of 2024
    ** In 2022, ASLN was down 67.9% 
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))